LEADER 03812nam 22006854a 450 001 9910777636203321 005 20230828220844.0 010 $a0-19-756195-0 010 $a1-280-83783-7 010 $a0-19-974906-X 010 $a1-4294-0273-3 035 $a(CKB)1000000000465632 035 $a(OCoLC)71794280 035 $a(CaPaEBR)ebrary10375127 035 $a(SSID)ssj0000154401 035 $a(PQKBManifestationID)11149353 035 $a(PQKBTitleCode)TC0000154401 035 $a(PQKBWorkID)10427223 035 $a(PQKB)11512995 035 $a(MiAaPQ)EBC3053633 035 $a(StDuBDS)EDZ0002341412 035 $a(Au-PeEL)EBL3053633 035 $a(CaPaEBR)ebr10375127 035 $a(CaONFJC)MIL83783 035 $a(EXLCZ)991000000000465632 100 $a20050504d2006 uy 0 101 0 $aeng 135 $aurcn||||||||| 181 $ctxt 182 $cc 183 $acr 200 10$aFibrinolytic and antithrombotic therapy$b[electronic resource] $etheory, practice, and management /$fRichard C. Becker, Frederick A. Spencer 205 $a2nd ed. 210 $aOxford ;$aNew York $cOxford University Press$d2006 215 $a1 online resource (421 p.) 225 1 $aOxford scholarship online 300 $aPreviously issued in print: 2006. 311 $a0-19-515564-5 320 $aIncludes bibliographical references and index. 327 $aHistorical perspectives in hemostasis, coagulation and fibrinolysis -- Vascular biology, thromboresistance and inflammation -- Atherosclerosis and arterial thrombosis -- Venous thromboembolism -- Cardiac chamber, aortic and valvular thromboembolism -- Fibrinolytic agents -- Aspirin -- Clopidogrel -- Platelet Glycoprotein IIb/IIIa receptor antagonists -- Aggrenox and cilostazol -- Novel platelet antagonists -- 327 $aCombination pharmacotherapy -- Facilitated percutaneous coronary intervention -- Thrombin-directed therapy -- Factor Xa inhibitors -- Direct thrombin inhibitors -- Novel anticoagulants -- Acute coronary syndromes -- Peripheral vascular disease and stroke -- Valvular heart disease and atrial fibrillation -- Plaque-stabilizing therapies -- 327 $aVenous thromboembolism prophylaxis -- Venous thromboembolism treatment -- Fundamentals and patient evaluation -- Platelet antagonists -- Anticoagulants -- Anticoagulation clinics and self-testing -- Platelet antagonists -- Anticoagulants -- Fibrinolytic agents. 330 8 $aThrombotic disorders of the circulatory system represent the leading cause of morbidity, mortality, and health care expenditure in the United States. The Second Edition of Fibrinolytic and Antithrombotic Therapy provides a practical, evidence-based approach to the managment of thrombotic disorders for all clinicians involved in the care of patients with these disorders. It provides not only vital conceptual information on fibrinolytic and antithrombotic therapy, but also the means to apply it to everyday decision making and patient care. Focusing on management guidelines and critical pathways, the text stresses practicality and usability. It will be a valuable resource for the wide range of clinicians involved in the care of patients with these disorders. 410 0$aOxford scholarship online. 606 $aThrombolytic therapy 606 $aFibrinolytic agents 606 $aThrombosis$xTreatment 615 0$aThrombolytic therapy. 615 0$aFibrinolytic agents. 615 0$aThrombosis$xTreatment. 676 $a616.1/3506 700 $aBecker$b Richard C$044739 701 $aSpencer$b Fredrick A.$cMD.$01563240 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910777636203321 996 $aFibrinolytic and antithrombotic therapy$93831484 997 $aUNINA